Rtw Investments 13F: Adds $3.4M to CMPX Stake

Rtw Investments recently boosted its stake in CMPX, adding 1,686,599 shares. This brings its total to 4,186,599 shares, valued at approximately $8.37 million, according to the latest SEC filing for the reporting period.

What Changed in Rtw Investments's CMPX Position

Rtw Investments increased its holdings in CMPX by 67%. Previously, the fund held 2,500,000 shares and added 1,686,599 more, resulting in a total of 4,186,599 shares. The value of these shares is reported to be around $8.37 million.

Other Institutional Activity in CMPX

Tang Capital Management maintained its position in CMPX with 16,790,809 shares, valued at about $88.32 million. Orbimed Advisors also held steady with 15,219,994 shares, worth approximately $80.51 million. Suvretta Capital Management added 125,000 shares, bringing its total to 14,307,379 shares, valued at $75.69 million. Meanwhile, BlackRock increased its stake by 117,456 shares to a total of 9,506,080 shares, valued at $50.29 million. Adage Capital Partners made a more significant move, adding 4,050,000 shares to reach 8,486,500 shares, valued at $44.89 million.

Compass Therapeutics, Inc. Stock Up 5.3%

Shares of CMPX are trading around $2.00. The company does not have a meaningful P/E ratio as it isn't currently profitable. CMPX's stock has a 52-week low of $1.50 and a high of $4.00. Its 50-day moving average is $2.10, and the 200-day moving average is $2.50.

Insider Buying and Selling at Compass Therapeutics, Inc.

On April 29, 2026, Jonathan Anderman, the General Counsel, bought 25,000 shares at an average price of $1.89. Neil Lerner, the Chief Accounting Officer, also purchased 15,000 shares on the same date at the same price. Earlier, on February 8, 2026, CEO Thomas Schuetz sold 36,687 shares at $6.52 each.

Analysts Set New Price Targets

On April 28, 2026, Canaccord Genuity maintained a 'buy' rating on CMPX with a price target of $7. Citizens reiterated its 'buy' rating with a target of $10. On April 27, HC Wainwright & Co. also reiterated a 'buy' rating, setting a target of $24, while D. Boral Capital maintained its 'buy' rating with a $30 target. The consensus among analysts is a 'buy', with an average target price of approximately $16.60 based on multiple opinions.

About CMPX

CMPX operates in the healthcare sector, focusing on developing and commercializing treatments to address unmet medical needs. The company is headquartered in the United States and works on innovative therapies across several medical fields.

Bottom Line

Rtw Investments's increased stake in CMPX suggests confidence in the company's potential. Investors often watch such filings to gauge institutional sentiment. It's important to remember that 13F filings reflect past positions and may not indicate current holdings.